Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 trial of zelicapavir in high-risk adults

Next Previous
Trial Profile

A phase 3 trial of zelicapavir in high-risk adults

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zelicapavir (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Enanta Pharmaceuticals

Most Recent Events

  • 08 Jan 2026 According to an Enanta Pharmaceuticals media release, company expects to align with U.S. Food and Drug Administration (FDA) on the adult phase 3 study design and registration pathway in the second quarter of 2026, following positive Phase 2b RSVHR results for zelicapavir, and plans to initiate a Phase 3 trial of zelicapavir in high-risk adults in the second half of 2026.
  • 08 Jan 2026 According to an Enanta Pharmaceuticals media release, company is continuing phase 3-enabling activities, including discussions with the U.S. Food and Drug Administration (FDA), following positive phase 2b RSVHR results for zelicapavir, for the treatment of respiratory syncytial virus (RSV).
  • 12 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top